Supplemental Table 1. Probe information for TAPBP polymorphisms
Loci
assay ID
rs3106189
C___2479333_10
rs2239841
Forward
GGCACCTTCACCTAACCAGA
Reverse
CCTCTAGTTCTTGGGCGATG
VIC
AGAGGAGGCTTAATGGCTGAG
FAM
AGAGGAGGCTTCATGGCTGAGG
rs3106190
C___2479337_20
rs2071888
C__11407883_1_
rs1059288
C___2479349_10
Supplemental table 2. Allele frequency and Hardy-Weinberg equilibrium in study subjects
Loci
Position
rs3106189
5'UTR
rs2239841
rs3106190
rs2071888
rs1059288
Amino acid
5'UTR
Intron3
Exon4
3'UTR
Genotype
change
Thr260Arg
G
AG
A
N
613
530
93
1236
C
AC
A
N
784
416
40
1240
G
CG
C
N
620
532
92
1244
C
CG
G
N
551
562
128
1241
T
CT
C
N
553
562
127
1242
MAF
Heterozygosity
HWE
0.290
0.412
0.139
0.200
0.320
0.088
0.288
0.410
0.127
0.330
0.442
0.383
0.329
0.441
0.366
Supplemental table 3. Genotype and haplotype distributions of TAPBP gene between the subjects with nasal polyps
and those without nasal polyps.
Nasal Polyp
Loci
position
Y
rs3106189
5'UTR
rs3106190
5'UTR
Intron3
139(49.8%) 352(50.1%)
AG
122(43.7%) 297(42.3%)
C
Exon4
3'UTR
_
180(65.2%) 450(63.7%)
234(33.1%)
A
8(2.9%)
22(3.1%)
G
141(50.0%) 353(50.2%)
CG
123(43.6%) 297(42.3%)
18(6.4%)
Recessive
125(44.6%) 316(45.0%)
CG
132(47.1%) 308(43.8%)
23(8.2%)
127(45.0%) 316(45.1%)
CT
132(46.8%) 307(43.8%)
-/-
p
OR((5% CI)
p
OR((5% CI)
p
0.92(0.73-1.15)
0.45
0.95(0.71-1.27)
0.73
0.72(0.40-1.28)
0.26
0.90(0.69-1.17)
0.42
0.89(0.66-1.21)
0.45
0.81(0.35-1.91)
0.64
0.92(0.73-1.16)
0.46
0.95(0.71-1.27)
0.73
0.72(0.41-1.29)
0.27
0.85(0.68-1.06)
0.16
0.91(0.68-1.22)
0.53
0.59(0.36-0.99)
0.04
0.85(0.68-1.06)
0.14
0.90(0.67-1.20)
0.48
0.59(0.36-0.99)
0.04
1.00(0.71-1.41)
0.99
1.02(0.70-1.49)
0.91
0.77(0.19-3.23)
0.73
79(11.2%)
T
23(8.2%)
OR((5% CI)
53(7.5%)
C
C
ht3
Dominant
54(7.7%)
88(31.9%)
G
rs1059288
18(6.5%)
AC
C
rs2071888
N
G
A
rs2239841
Codominant
genotype
78(11.1%)
230(81.9%) 581(82.9%)
ht3/-
48(17.1%)
113(16.1%)
ht3/ht3
3(1.1%)
7(1.0%)
MAF: minor allele frequency, OR: odds ratio, CI: confidence interval. P-value is adjusted for age, sex, smoking and atopy as co-variables.
Supplemental table 4. Comparisons of haplotype distributions of TAPBP between the subjects with AERD and those with ATA
MAF
Global analysis
Haplotype
Referent analysis
p-
AERD
ATA
OR
pOR
value
value
ht1
0.616
0.685
1
ht2
0.219
0.194
1.24(0.97-1.59)
0.09
ht3
0.104
0.085
1.19(1.00-1.41)
0.05
1.23(1.1-1.38)
0.0003
ht4
0.060
0.035
1.26(1.08-1.46)
0.003
ht5
0.000
0.001
.
.
ht6
0.002
0.000
.
.
Supplemental table 5. Associations of TAPBP haplotypes with decline of FEV1 on aspirin provocation
Global pHaplotype
MAF
Mean±SD
value
ht1
0.669
7.27±10.61
ht2
0.199
8.03±11.94
ht3
0.089
9.04±12.94
ht4
0.042
9.03±11.98
ht5
0.0004
3.00
ht6
0.0004
27.00
0.003
Supplemental Table 6. Regression analysis of TAPBP polymorphisms with the decline of FEV1 normalized with total dosages of aspirin
Loci
C/C
C/R
R/R
Pa
Pb
Pc
rs3106189
601(1.81±8.50)
516(1.65±6.29)
87(1.97±6.56)
0.91
0.78
0.78
rs2239841
766(1.75±7.77)
405(1.32±4.93)
37(2.18±7.61)
0.51
0.38
0.70
rs3106190
607(1.79±8.46)
519(1.65±6.28)
86(1.99±6.59)
0.95
0.80
0.75
rs2071888
541(1.74±8.71)
547(1.77±6.45)
121(1.70±5.63)
0.97
0.94
0.96
rs1059288
543(1.74±8.69)
547(1.77±6.45)
120(1.71±5.66)
0.98
0.96
0.97
1008(1.74±7.74) 189(1.71±5.84)
11(3.47±7.99)
0.71
0.80
0.53
ht3
% fall of FEV1 normalized with total dosages of aspirin used in challenge test was calculated as % fall of FEV1 divided by total dose of aspirin x
100.